Literature DB >> 19260952

Peritoneal fluid adipokines: ready for prime time?

R Wiest1, F Leidl, A Kopp, J Weigert, M Neumeier, C Buechler, J Schoelmerich, A Schäffler.   

Abstract

BACKGROUND: Visceral adipose tissues secret a variety of adipokines; however, it is not known whether they are present in the peritoneal fluid. It was the aim of this study to investigate peritoneal fluid concentrations of novel (cartonectin, omentin) and classical adipokines (leptin, adiponectin, resistin, visfatin) in patients with ascites.
MATERIAL AND METHODS: Ninety-six patients (71 men and 25 women) undergoing paracentesis were included. Of these, 76 suffered from liver cirrhosis. Adipokines were measured by enzyme-linked immunosorbent assay or Western blot.
RESULTS: Each adipokine was detected in ascites with a broad range. Serum-ascites ratios (SAR) correlated with clinical and laboratory parameters. The main variables influencing peritoneal fluid adipokine concentrations were body mass index (BMI), local inflammation, systemic inflammation and serum adipokine concentrations. Resistin was significantly higher in patients with peritonitis and showed a positive correlation with peripheral leucocytes (white blood cell count). Leptin was correlated with the underlying disease. Visfatin correlated with peripheral white blood cell and C-reactive protein levels. Omentin expression was correlated with ascitic leucocyte count, ascitic albumin concentration and low albumin SAR. BMI was correlated positively with ascitic leptin levels and cartonectin protein levels.
CONCLUSIONS: Peritoneal fluid adipokine concentrations are characterized by individual SARs, depend on the presence of peritonitis, and correlate with underlying disease, BMI and systemic inflammation. The data open a new field of research on the role of the peritoneum and visceral adipokines in gastrointestinal diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19260952     DOI: 10.1111/j.1365-2362.2009.02085.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  2 in total

Review 1.  Adipokines in Liver Cirrhosis.

Authors:  Christa Buechler; Elisabeth M Haberl; Lisa Rein-Fischboeck; Charalampos Aslanidis
Journal:  Int J Mol Sci       Date:  2017-06-29       Impact factor: 5.923

2.  Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients.

Authors:  Susanne Feder; Elisabeth M Haberl; Marlen Spirk; Thomas S Weiss; Reiner Wiest; Christa Buechler
Journal:  Clin Exp Med       Date:  2020-02-20       Impact factor: 3.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.